✨ Free AI Report
Neos Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Neos Therapeutics, Inc.
Company Research

Neos Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Neos Therapeutics, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Niche ADHD pharma play with established products but constrained by micro-cap valuation and thin pipeline depth. Neos operates as a niche pharmaceutical company with established ADHD products generating near-$63M revenue, but faces significant headwinds. Market cap of $57M is less than annual revenue, signaling investor concern. The company operates.

What is Neos Therapeutics, Inc.'s industry? Neos Therapeutics, Inc. (neostx.com) operates in Pharmaceuticals. AskCyborg classifies Neos Therapeutics, Inc. under Pharmaceuticals in its company registry.

Neos Therapeutics develops extended-release drugs for CNS disorders using proprietary technology platform. The company manufactures and markets Adzenys XR-ODT amphetamine and Cotempla XR-ODT methylphenidate for ADHD t...

4/ 10Mixed

Cyborg Score thesis

Niche ADHD pharma play with established products but constrained by micro-cap valuation and thin pipeline...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Neos Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Neos Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Neos Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Neos Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Neos Therapeutics, Inc. Overview

Pro stress-test →

Neos Therapeutics develops extended-release drugs for CNS disorders using proprietary technology platform. The company manufactures and markets Adzenys XR-ODT amphetamine and Cotempla XR-ODT methylphenidate for ADHD treatment, plus generic Tussionex for cough and cold symptoms. As of May 24, 2026, the market cap is $57.23M.

Strategic Profile

Pro stress-test →

The company generated $62.5 million in annual revenue in 2026, positioning it as a specialized ADHD-focused pharmaceutical company. Neos is advancing clinical-stage pipeline with NT0502 for the treatment of sialorrhea in patients with neurological conditions, though its core business remains ADHD products and generic cough/cold formulations.

Competitive Landscape

Pro stress-test →

Top competitors include Cingulate, SciNeuro and STALICLA. Neos competes in the ADHD treatment space with branded and extended-release formulations, though its scale is significantly smaller than larger pharma players. The company also competes in generic cough/cold markets with Tussionex, a more commoditized segment.

Industry Context

Neos Therapeutics, Inc. operates in Pharmaceuticals.

Key facts

Founded: 2008 · Headquarters: Grand Prairie, Texas, US · Employees: 15 · Revenue: $62.5M (2026) · Market cap: $57.23M (as of May 2026)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Neos Therapeutics, Inc..

  • Generated $62.5M revenue in 2026 with only 15 employees, indicating operational efficiency but potential capacity constraints for scaling or pipeline advancement.
  • Market cap of $57.23M as of May 2026 sits below trailing revenue, reflecting investor skepticism about growth prospects or profitability trajectory despite established product commercialization.
+1 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2026Market cap assessed at $57.23M
  • February 2026Pipeline data updated, NT0502 clinical trial status confirmed
  • +1 moreTrack every material event for Neos Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Neos Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Cingulate Inc.ADHD treatment competitor→Adlon TherapeuticsADHD treatment developer→Aytu BioPharmaExtended-release ADHD medications including Cotempla XR-ODT competitor→NaurexCNS disorder and ADHD treatment developer→

Compare Neos Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Neos Therapeutics, Inc. operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Neos Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Neos Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Neos Therapeutics, Inc. do this quarter?”
“Is Neos Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Neos Therapeutics, Inc. do?+
Neos Therapeutics develops extended-release drugs for CNS disorders using proprietary technology platform. The company manufactures and markets Adzenys XR-ODT amphetamine and Cotempla XR-ODT methylphenidate for ADHD t...
What is Neos Therapeutics, Inc.'s Cyborg Score?+
Neos Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Neos Therapeutics, Inc.'s main competitors?+
Named competitors include Cingulate Inc., Adlon Therapeutics, Aytu BioPharma, Naurex. The full competitive landscape is in the AskCyborg report.
How can I get the full Neos Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Neos Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Neos Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.8Cingulate Inc.